Number of Shares and Voting Rights of ADOCIA as of July 31st, 2024
Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter
Month |
Date |
Total number of
|
Total number of
|
Total number of
|
July |
|
15,046,413* |
17,169,834 |
17,156,697 |
* Over July, no new shares have been issued in connection with the PACEO financing line, whose main characteristics are described in our press release of
(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or” net” voting rights) is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement.
About
The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with a first application in pancreatic cells transplantation; 4) AdoGel®, a long-acting drug delivery platform.
Disclaimer
This press release contains certain forward-looking statements concerning
T
he forward-looking statements contained in this press release are also subject to risks not yet known to
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829524815/en/
CEO
contactinvestisseurs@adocia.com
Tel : +33 4 72 610 610
www.adocia.com
Ulysse Communication
adocia@ulysse-communication.com
+ 33 (0)6 87 88 47 26
Source: